drugset / Trial / NCT03911453
Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm window of opportunity trial conducted in patients with early stage triple negative breast tumors to evaluate if treatment with a Poly(ADP-ribose) polymerase (PARP) inhibitor will increase expression of programmed cell death-1 with ligand (PD-L1) in triple negative breast tumors.
Timeline
- Start
- 2019-04-19
- Primary completion
- 2021-07-16
- Completion
- 2021-07-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rucaparib | Small molecule | 300 mg | — |
| Subject | Rucaparib | Small molecule | 400 mg | — |
| Subject | Rucaparib | Small molecule | 500 mg | — |
| Subject | Rucaparib | Small molecule | 600 mg | — |